Therapy News and Research

RSS

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

GE Healthcare today announced results from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial at the 2012 Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Cancer patients with annual incomes below $50,000 less likely to participate in clinical trials

Cancer patients with annual household incomes below $50,000 were less likely to participate in clinical trials than patients with annual incomes of $50,000 or higher, and were more likely to be concerned about how to pay for clinical trial participation.

4 Jun 2012

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC).

4 Jun 2012

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.

4 Jun 2012

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces that favorable clinical results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate INNO-206 in patients with advanced solid tumors, primarily soft tissue sarcomas, are being presented today at the American Society of Clinical Oncology (ASCO) conference in Chicago.

4 Jun 2012

Affibody, GE Healthcare partner to develop Her2-targeted PET imaging agent

GE Healthcare signed an agreement with Affibody AB to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.

4 Jun 2012

Study reveals why GBM is highly resistant to current chemotherapies

New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.

2 Jun 2012

New evidence of important role of next-generation sequencing in cancer treatment

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced results from two studies using next-generation sequencing (NGS) to provide actionable information about genomic tumor alterations in individual patients' cancers across all solid tumor types.

2 Jun 2012

Socioeconomic status of patient linked to choice of treatment

Though it would seem logical, cancer patients don't always choose therapies with the best chance for survival-cost and side effects are also major considerations. Little has been known about the extent to which cost and side effects influence a patient's treatment decision. Now, new findings by Fox Chase Cancer Center researchers reveals that a patient's socioeconomic status, more than any other characteristic-such as age or disease site-is predictive of whether he or she will favor high efficacy, low cost or low toxicity when choosing a treatment.

2 Jun 2012

New molecular test panel to enhance reliability of thyroid biopsy testing

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal.

From Quest Diagnostics 2 Jun 2012

Engineered proteins demonstrate flu-fighting potency

Computer-designed proteins are under construction to fight the flu. Researchers are demonstrating that proteins found in nature, but that do not normally bind the flu, can be engineered to act as broad-spectrum antiviral agents against a variety of flu virus strains, including H1N1 pandemic influenza.

2 Jun 2012

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer.

2 Jun 2012

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications.

2 Jun 2012

Two tumor suppressor genes function to disrupt overactive EGFR signaling

Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed resistance to these drugs and are therefore no longer responsive to drug treatment.

2 Jun 2012

Non-invasive stimulation of cerebellum helps individuals learn new walking patterns

In a step towards improving rehabilitation for patients with walking impairments, researchers from the Kennedy Krieger Institute found that non-invasive stimulation of the cerebellum, an area of the brain known to be essential in adaptive learning, helped healthy individuals learn a new walking pattern more rapidly.

2 Jun 2012

HealthSouth to build comprehensive physical rehabilitation hospital in greater Orlando

HealthSouth Corporation today announced it has received permission from the state to proceed with building a comprehensive physical rehabilitation hospital in the greater Orlando, Fla., market. The 50-bed hospital will provide comprehensive physical rehabilitation to patients who have experienced stroke, trauma, brain and orthopedic injuries or other major illness or injuries.

2 Jun 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal tumors resistant to the only other available therapy, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research.

2 Jun 2012

Therapy News and Research

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Cancer patients with annual incomes below $50,000 less likely to participate in clinical trials

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

Affibody, GE Healthcare partner to develop Her2-targeted PET imaging agent

Study reveals why GBM is highly resistant to current chemotherapies

New evidence of important role of next-generation sequencing in cancer treatment

Socioeconomic status of patient linked to choice of treatment

New molecular test panel to enhance reliability of thyroid biopsy testing

Engineered proteins demonstrate flu-fighting potency

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Two tumor suppressor genes function to disrupt overactive EGFR signaling

Non-invasive stimulation of cerebellum helps individuals learn new walking patterns

HealthSouth to build comprehensive physical rehabilitation hospital in greater Orlando

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News